Stock Analysis of Uniqure NV (QURE) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code QURE
Close 5.01
Change -0.060 / 1.18 %
Volume 372196
Vol Change 24542.00 / 7.06 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthMild Bullish
Growth Index Low Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Poor Stability Stock


Fundamental View of Uniqure NV
PE (TTM)

-201.64

Very Poor
Price / Book

215.44

Very Poor
Price / Sales

3150.10

Very Poor
Piotroski F Score

3.0

Not Good
Market Cap

243232 K

Enterprise Value

111965 K

ROA (TTM)

-36.68

Very Poor
ROE (TTM)

-106.84

Very Poor
Net Margin (TTM)

-1562.22

Very Poor
Revenue

5.09 %

111899 K
Net Profit

80.19 %

-228465.00 K
Debt to Equity

0.530

Good
Altman Z Score

-1.09

Very Poor
Quick Ratio

8.68

Excellent
Cash Ratio

8.39

Excellent


Highs/Lows of Uniqure NV
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week4.92 1.83 % 1.54 % 5.1754.8415-May-2414-May-24
Two Week4.69 6.82 % 3.42 % 5.194.6109-May-2406-May-24
One Month4.67 7.28 % 5.60 % 5.194.2509-May-2430-Apr-24
Three Month5.85 14.36 % 5.95 % 6.874.2528-Feb-2430-Apr-24
Six Months6.89 27.29 % 17.48 % 8.664.2515-Dec-2330-Apr-24
One year20.56 75.63 % 27.52 % 21.884.2522-May-2330-Apr-24
Two year14.15 64.59 % 29.70 % 28.2554.2529-Nov-2230-Apr-24
Five year59.74 91.61 % 85.46 % 28.2554.2529-Nov-2230-Apr-24
Ten year9.61 47.87 % 182.41 % 82.494.2520-Jun-1930-Apr-24


Technical View of Uniqure NV
RSI

55.39

Neutral
MACD

0.0238

Strong Bullish
ADX

18.47

Bullish
Super Trend

4.33

Mild Bullish
Williams %R

-19.15

Mild Bearish
CCI

85.15

Strong Bearish


EMA 5

5.00

Bullish
EMA 15

4.89

Mild Bullish
EMA 50

5.04

Whipsaw
EMA 100

5.59

Mild Bearish
SMA 100

5.47

Mild Bearish
SMA 200

6.35

Mild Bearish
SMA 5 / 20

4.99 / 4.76

Mild Bullish
SMA 15 / 50

4.81 / 4.95

Mild Bearish
SMA 50 / 200

4.95 / 6.35

Mild Bearish




Charts of Uniqure NV


Returns of Uniqure NV with Peers
Period / StockQUREPYXSGBIOCHRS
1 Week1.83%-4.38%22.41%11.58%
1 Mth7.28%-14.08%22.82%-1.40%
3 Mth-14.36%-23.85%71.43%-23.19%
6mth-27.29%190.21%222.47%-0.469%
1 Year-75.63%11.86%-12.65%-57.77%
2 Year-64.59%90.37%-36.46%-73.20%
5 Years-91.61%---88.57%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Uniqure NV with Peers
Ratio / StockQUREPYXSGBIOCHRS
PE-201.64-744.51-341.78-3.84
P/B215.44287.90268.90-1.46
ROA-36.68-30.79-46.09-10.41
ROE-106.84-38.78-78.680
Debt To Equity0.5300.00980.0400-2.47
Revenue111899 K
5.09 % 		0
% 		3026.00 K
243.86 % 		257244 K
21.89 %
Net Income-228465.00 K
80.19 % 		-94294.00 K
21.89 % 		-123831.00 K
9.37 % 		-237892.00 K
18.46 %


Technicals of Uniqure NV with Peers
Technical / StockQUREPYXSGBIOCHRS-
ADX18.4710.8424.0815.40
CMF-0.101-0.268-0.252-0.074
MFI62.0741.2759.8653.07
RSI55.3940.8057.8448.12
MACD Abv SignalTrueFalseTrueTrue
Price Above 50 MATrueFalseTrueFalse-
Price Above 200 MAFalseTrueTrueFalse-


About : Uniqure NV

Address : Paasheuvelweg 25, Amsterdam, Netherlands, 1105 BP
Tel : 31 20 240 6000
URL : https://www.uniqure.com
Code : QURE, ISIN : NL0010696654, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 20_Jun_2007
Employee Count : 480

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.


Note : All Data Generated at the End of Trading Hours (EOD Data)